Sean Duffy Sells 230,479 Shares of Omada Health (NASDAQ:OMDA) Stock

Omada Health, Inc. (NASDAQ:OMDA) CEO Sean Duffy sold 230,479 shares of the firm’s stock in a transaction that occurred on Monday, January 12th. The stock was sold at an average price of $15.60, for a total transaction of $3,595,472.40. Following the sale, the chief executive officer owned 126,644 shares in the company, valued at approximately $1,975,646.40. This trade represents a 64.54% decrease in their position. The sale was disclosed in a legal filing with the SEC, which is available through this hyperlink.

Omada Health Stock Performance

Shares of OMDA opened at $15.65 on Friday. Omada Health, Inc. has a fifty-two week low of $14.14 and a fifty-two week high of $28.40. The company has a market capitalization of $906.29 million and a PE ratio of -62.60. The stock has a fifty day moving average of $16.94 and a two-hundred day moving average of $19.98.

Institutional Inflows and Outflows

Hedge funds have recently bought and sold shares of the business. Raymond James Financial Inc. purchased a new stake in Omada Health during the second quarter worth approximately $32,000. Strs Ohio acquired a new position in shares of Omada Health during the 3rd quarter valued at $38,000. Rakuten Investment Management Inc. purchased a new stake in Omada Health during the 3rd quarter worth $49,000. JPMorgan Chase & Co. acquired a new stake in Omada Health in the 3rd quarter valued at $82,000. Finally, MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. purchased a new position in Omada Health in the third quarter valued at about $95,000.

Analyst Ratings Changes

A number of brokerages have issued reports on OMDA. BMO Capital Markets initiated coverage on Omada Health in a research note on Thursday, November 13th. They issued an “outperform” rating and a $27.00 price target on the stock. Evercore ISI raised their target price on shares of Omada Health from $27.00 to $28.00 and gave the stock an “outperform” rating in a research report on Friday, November 7th. Weiss Ratings reaffirmed a “sell (d)” rating on shares of Omada Health in a research report on Wednesday, October 8th. Wells Fargo & Company started coverage on shares of Omada Health in a research note on Thursday, January 8th. They set an “equal weight” rating and a $17.00 price target on the stock. Finally, The Goldman Sachs Group set a $29.00 price objective on shares of Omada Health in a research note on Friday, January 9th. Eight investment analysts have rated the stock with a Buy rating, three have given a Hold rating and one has issued a Sell rating to the company’s stock. According to data from MarketBeat.com, Omada Health has an average rating of “Moderate Buy” and an average price target of $25.40.

About Omada Health

Omada Health is a digital health company that specializes in the prevention and management of chronic conditions through personalized, technology-driven programs. The company’s platform combines data analytics, behavioral science and human coaching to support individuals at risk for or living with conditions such as prediabetes, type 2 diabetes, hypertension and musculoskeletal disorders. Participants access the program via a mobile app or web portal, where they receive tailored curriculum, feedback on health metrics and ongoing virtual coaching.

In addition to its core disease-management offerings, Omada Health has expanded its services to include mental health support and digital therapeutics for weight management.